Table 2.
Current treatment (≥1.5% of the entire study population) by CAT score domain in all and individual regions
| Entire study population
|
5EU
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall
|
0–9
|
10–19
|
20–29
|
30–40
|
Overall
|
0–9
|
10–19
|
20–29
|
30–40
|
|
| (N=2,166, 100%) | (n=207, 9.6%) | (n=609, 28.1%) | (n=988, 45.6%) | (n=362, 16.7%) | (N=1,242, 100%) | (n=138, 11.1%) | (n=405, 32.6%) | (n=512, 41.2%) | (n=187, 15.1%) | |
| Current treatment, n (%) | ||||||||||
| Missing, n | 6 | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 0 |
| Short-acting therapy | ||||||||||
| SABA, SAMA, SABA/SAMA alonea | 128 (5.9) | 33 (16.1) | 35 (5.8) | 50 (5.1) | 10 (2.8) | 68 (5.5) | 19 (13.9) | 21 (5.2) | 23 (4.5) | 5 (2.7) |
| Maintenance therapies | ||||||||||
| Bronchodilator monotherapy | ||||||||||
| LAMA alone | 313 (14.5) | 59 (28.8) | 141 (23.2) | 96 (9.7) | 17 (4.7) | 236 (19.0) | 45 (32.9) | 112 (27.7) | 69 (13.5) | 10 (5.4) |
| LABA alone | 83 (3.8) | 16 (7.8) | 27 (4.4) | 33 (3.4) | 7 (1.9) | 73 (5.9) | 16 (11.7) | 26 (6.4) | 25 (4.9) | 6 (3.2) |
| Bronchodilator dual therapy | ||||||||||
| LAMA+LABA | 129 (6.0) | 16 (7.8) | 39 (6.4) | 58 (5.9) | 16 (4.4) | 123 (9.9) | 15 (11.0) | 38 (9.4) | 55 (10.8) | 15 (8.0) |
| Triple therapyb | ||||||||||
| LAMA+ICS/LABA | 525 (24.3) | 31 (15.1) | 130 (21.4) | 243 (24.7) | 121 (33.5) | 385 (31.1) | 18 (13.1) | 92 (22.7) | 181 (35.4) | 94 (50.3) |
| LAMA+LABA+ICS | 32 (1.5) | 2 (1.0) | 11 (1.8) | 12 (1.2) | 7 (1.9) | 27 (2.2) | 2 (1.5) | 9 (2.2) | 11 (2.2) | 5 (2.7) |
| ICS-based therapies not including dual LAMA+LA BA component | ||||||||||
| ICS alone | 39 (1.8) | 4 (2.0) | 12 (2.0) | 14 (1.4) | 9 (2.5) | 21 (1.7) | 2 (1.5) | 9 (2.2) | 8 (1.6) | 2 (1.1) |
| ICS/LABA alone | 432 (20.0) | 35 (17.1) | 109 (17.9) | 214 (21.7) | 74 (20.5) | 194 (15.7) | 15 (11.0) | 67 (16.5) | 86 (16.8) | 26 (13.9) |
| ICS+LAMA | 27 (1.3) | 2 (1.0) | 9 (1.5) | 8 (0.8) | 8 (2.2) | 17 (1.4) | 1 (0.7) | 6 (1.5) | 4 (0.8) | 6 (3.2) |
| ICS+LABA | 20 (0.9) | 1 (0.5) | 2 (0.3) | 8 (0.8) | 9 (2.5) | 10 (0.8) | 1 (0.7) | 2 (0.5) | 3 (0.6) | 4 (2.1) |
| ICS/LABA+LTRA | 58 (2.7) | 0 | 17 (2.8) | 32 (3.3) | 9 (2.5) | 3 (0.2) | 0 | 1 (0.3) | 2 (0.4) | 0 |
| ICS/LABA+xanthines | 112 (5.2) | 2 (1.0) | 11 (1.8) | 76 (7.7) | 23 (6.4) | 9 (0.7) | 1 (0.7) | 1 (0.3) | 6 (1.2) | 1 (0.5) |
| ICS+xanthines | 30 (1.4) | 0 | 5 (0.8) | 22 (2.2) | 3 (0.8) | 1 (0.1) | 0 | 1 (0.3) | 0 | 0 |
| Other maintenance therapies | ||||||||||
| Xanthines alone | 61 (2.8) | 0 | 16 (2.6) | 34 (3.5) | 11 (3.1) | 4 (0.3) | 0 | 0 | 4 (0.8) | 0 |
| Other | 171 (7.9) | 4 (2.0) | 44 (7.2) | 86 (8.7) | 37 (10.2) | 69 (5.6) | 2 (1.5) | 20 (4.9) | 34 (6.7) | 13 (7.0) |
|
| ||||||||||
|
USA
|
China
|
|||||||||
|
Overall
|
0–9
|
10–19
|
20–29
|
30–40
|
Overall
|
0–9
|
10–19
|
20–29
|
30–40
|
|
| (N=413, 100%) | (n=60, 14.5%) | (n=116, 28.1%) | (n=172, 41.6%) | (n=65, 15.7%) | (N=511, 100%) | (n=9, 1.8%) | (n=88, 17.2%) | (n=304, 59.5%) | (n=110, 21.5%) | |
|
| ||||||||||
| Current treatment, n (%) | ||||||||||
| Missing, n | 3 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Short-acting therapy | ||||||||||
| SABA, SAMA, SABA/SAMA alonea | 41 (10.0) | 13 (22.0) | 9 (7.8) | 18 (10.5) | 1 (1.5) | 19 (3.7) | 1 (11.1) | 5 (5.7) | 9 (3.0) | 4 (3.7) |
| Maintenance therapies | ||||||||||
| Bronchodilator monotherapy | ||||||||||
| LAMA alone | 73 (17.8) | 14 (23.7) | 29 (25.2) | 24 (14.0) | 6 (9.2) | 4 (0.8) | 0 | 0 | 3 (1.0) | 1 (0.9) |
| LABA alone | 5 (1.2) | 0 | 1 (0.9) | 4 (2.3) | 0 | 5 (1.0) | 0 | 0 | 4 (1.3) | 1 (0.9) |
| Bronchodilator dual therapy | ||||||||||
| LAMA+LABA | 5 (1.2) | 1 (1.7) | 1 (0.9) | 2 (1.2) | 1 (1.5) | 1 (0.2) | 0 | 0 | 1 (0.3) | 0 |
| Triple therapyb | ||||||||||
| LAMA+ICS/LABA | 132 (32.2) | 13 (22.0) | 37 (32.2) | 60 (35.1) | 22 (33.9) | 8 (1.6) | 0 | 1 (1.1) | 2 (0.7) | 5 (4.6) |
| LAMA+LABA+ICS | 5 (1.2) | 0 | 2 (1.7) | 1 (0.6) | 2 (3.1) | 0 | 0 | 0 | 0 | 0 |
| ICS-based therapies not including dual | LAMA+LA | BA component | ||||||||
| ICS alone | 7 (1.7) | 1 (1.7) | 1 (0.9) | 2 (1.2) | 3 (4.6) | 11 (2.2) | 1 (11.1) | 2 (2.3) | 4 (1.3) | 4 (3.7) |
| ICS/LABA alone | 106 (25.9) | 15 (25.4) | 27 (23.5) | 45 (26.3) | 19 (29.2) | 132 (25.9) | 5 (55.6) | 15 (17.0) | 83 (27.3) | 29 (26.6) |
| ICS+LAMA | 10 (2.4) | 1 (1.7) | 3 (2.6) | 4 (2.3) | 2 (3.1) | 0 | 0 | 0 | 0 | 0 |
| ICS+LABA | 6 (1.5) | 0 | 0 | 4 (2.3) | 2 (3.1) | 4 (0.8) | 0 | 0 | 1 (0.3) | 3 (2.8) |
| ICS/LABA+LTRA | 1 (0.2) | 0 | 1 (0.9) | 0 | 0 | 54 (10.6) | 0 | 15 (17.1) | 30 (9.9) | 9 (8.3) |
| ICS/LABA+xanthines | 0 | 0 | 0 | 0 | 0 | 103 (20.2) | 1 (11.1) | 10 (11.4) | 70 (23.0) | 22 (20.2) |
| ICS+xanthines | 1 (0.2) | 0 | 0 | 1 (0.6) | 0 | 28 (5.5) | 0 | 4 (4.6) | 21 (6.9) | 3 (2.8) |
| Other maintenance therapies | ||||||||||
| Xanthines alone | 0 | 0 | 0 | 0 | 0 | 57 (11.2) | 0 | 16 (18.2) | 30 (9.9) | 11 (10.1) |
| Other | 18 (4.4) | 1 (1.7) | 4 (3.5) | 6 (3.5) | 7 (10.8) | 84 (16.5) | 1 (11.1) | 20 (22.7) | 46 (15.1) | 17 (15.6) |
Notes:
a
Either maintenance or rescue medication;
b
triple therapy defined as a single LABA, a single LAMA and a single ICS therapy only.
Abbreviations: 5EU, France, Germany, Italy, Spain and the UK; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.